Enhancing diversity in clinical trial enrollment through community engagement
Official title: Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Run by Dana-Farber Cancer Institute · NCT06469307 · Data updated 2026-11-12
This study is trying to see if getting feedback from patients and community members can help make clinical trials for blood cancer and leukemia more inclusive and diverse.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | December 9, 2024 |
| Main results expected | January 1, 2027 |
| Study ends | January 30, 2028 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT06469307 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include English-speaking adults aged 18 or older who are in remission from blood cancer for more than one year.
✕Probably not a fit
Patients who are unable to provide consent, are under 18 years old, or do not speak English may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research focuses on improving inclusion and diversity in clinical trial enrollment for blood cancer and leukemia by implementing a community-based protocol review process called DIVERSE. Participants, including patients and community members, will undergo specialized training to provide feedback on clinical trials in development. The study aims to assess the feasibility, acceptability, and preliminary efficacy of this process over an 18-month period. The initiative is supported by the National Cancer Institute and the American Society of Clinical Oncology.
Why it matters
Potential benefit: If successful, this approach could lead to more diverse representation in clinical trials, ultimately improving treatment outcomes for underrepresented populations.
How similar studies have gone: While the approach of community-based participatory research is gaining traction, this specific protocol review process is novel and has not been extensively tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
CAB Participant Inclusion Criteria: * Age 18 or older * English speaking * Ability to understand and willingness to provide oral consent * DFCI patient who are in remission from a blood cancer \>1 year will be preferred. CAB Participant Exclusion Criteria: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers \<18 years old) * Prisoners. * Unwilling/unable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1 * Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed. * Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews. Investigator Participant Inclusion Criteria: * Age 18 older * English Speaking * Site or Principal investigator * Not a member of the research team
Where it's running
-
Dana-Farber Cancer Institute
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Andrew Hantel, MD — Dana-Farber Cancer Institute
- Study coordinator: Andrew Hantel, MD
- Email: Andrew_Hantel@dfci.harvard.edu
- Phone: 617-582-9394
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
Targeting measurable residual AML with tagraxofusp plus azacitidine and venetoclax
This trial tests whether adding tagraxofusp to azacitidine and venetoclax can safely help control measurable residual acute myeloid leukemia (AML) in adults who are in remission but still have detectable disease.
-
Telehealth music therapy for cognitive difficulties in blood cancer survivors
This program will test whether telehealth music therapy can help adults who survived leukemia, lymphoma, or myeloma and who are having trouble with memory, attention, or thinking.
-
Platform for Rare Blood Disorders in Europe
This study is trying to gather and share information about rare blood disorders across Europe to help researchers understand these conditions better and improve treatment options for patients.
-
Improving quality of life for blood cancer patients receiving cellular therapy
This study is testing a new palliative care program called PEACE to see if it can improve the quality of life for blood cancer patients getting cellular therapy.
-
Improving leukemia diagnosis using artificial intelligence
This study is testing whether an artificial intelligence system can improve the diagnosis of leukemia by comparing its accuracy and speed to traditional methods using a large set of blood samples.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.